
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_28, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1,3 DIMETHYLURIC ACIDE1 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_175, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_996, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP4 HYDROXYDEBRISOQUINED6 CONTROLS FORMATION OF 4 HYDROXYDEBRISOQUINE</TD><TD>BC SATISFIED ASSERTION_1066, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP4 HYDROXYATOMOXETINED6 CONTROLS FORMATION OF 4 HYDROXYATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_304, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLROSUVASTATINC9 CONTROLS FORMATION OF N DESMETHYLROSUVASTATIN</TD><TD>BC SATISFIED ASSERTION_244, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLSERTRALINEC19 CONTROLS FORMATION OF N DESMETHYLSERTRALINE</TD><TD>BC SATISFIED ASSERTION_960, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLATOMOXETINEC19 CONTROLS FORMATION OF N DESMETHYLATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_487, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPHYDROXYBUPROPIONB6 CONTROLS FORMATION OF HYDROXYBUPROPION</TD><TD>BC SATISFIED ASSERTION_1186, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1A3 METHYLXANTHINE CONTROLS FORMATION OF 3 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_264, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2</TD><TD>CYP1A3 METHYLXANTHINE CONTROLS FORMATION OF 3 METHYLXANTHINE, THEOPHYLLINE HAS METABOLITE 3 METHYLXANTHINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6</TD><TD>CYPHYDROXYBUPROPIONB6 CONTROLS FORMATION OF HYDROXYBUPROPION, BUPROPION HAS METABOLITE HYDROXYBUPROPION, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>CYPN DESMETHYLATOMOXETINEC19 CONTROLS FORMATION OF N DESMETHYLATOMOXETINE, ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>CYPN DESMETHYLSERTRALINEC19 CONTROLS FORMATION OF N DESMETHYLSERTRALINE, SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>CYPN DESMETHYLROSUVASTATINC9 CONTROLS FORMATION OF N DESMETHYLROSUVASTATIN, ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>CYP4 HYDROXYATOMOXETINED6 CONTROLS FORMATION OF 4 HYDROXYATOMOXETINE, ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE, RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP2E1 DIMETHYLURIC ACID VIA CYP2E1</TD><TD>CYP1,3 DIMETHYLURIC ACIDE1 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID, THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID, THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID, </TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, ACYCLOVIR INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, ALLOPURINOL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CAFFEINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, DISULFIRAM INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, FAMOTIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, METHOXSALEN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, PHENYLPROPANOLAMINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, TERBINAFINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, VEMURAFENIB INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, VERAPAMIL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, PROPAFENONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, NORFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, MEXILETINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CIPROFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CIMETIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, AMIODARONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL INHIBITS TRANSFORMATION OF BUPROPION TO HYDROXYBUPROPION VIA CYP2B6</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, CLOPIDOGREL INHIBITS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL INHIBITS TRANSFORMATION OF BUPROPION TO HYDROXYBUPROPION VIA CYP2B6</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, PRASUGREL INHIBITS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS TRANSFORMATION OF BUPROPION TO HYDROXYBUPROPION VIA CYP2B6</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, TICLOPIDINE INHIBITS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, ARMODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, ESOMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, FELBAMATE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, ARMODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, ESOMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, FELBAMATE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF SERTRALINE TO N DESMETHYLSERTRALINE VIA CYP2C19</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, CAPECITABINE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, COTRIMOXAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, ETRAVIRINE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, FLUVASTATIN INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, METRONIDAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, MICONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, OXANDROLONE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, SULFINPYRAZONE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, TIGECYCLINE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, ZAFIRLUKAST INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, VORICONAZOLE N OXIDE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, VORICONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, TERIFLUNOMIDE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, FLUCONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, AMIODARONE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '3-METHYLXANTHINE 'THEOPHYLLINE 'CYP2E1)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '3-METHYLXANTHINE 'THEOPHYLLINE 'CYP3A4)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '1,3-DIMETHYLURIC-ACID 'THEOPHYLLINE 'CYP1A2)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         'N-DESMETHYLATOMOXETINE 'ATOMOXETINE 'CYP2D6)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '4-HYDROXYATOMOXETINE 'ATOMOXETINE 'CYP2C19)</TD></TR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, ACYCLOVIR INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, ALLOPURINOL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CAFFEINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, DISULFIRAM INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, FAMOTIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, METHOXSALEN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, PHENYLPROPANOLAMINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, TERBINAFINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, VEMURAFENIB INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, PROPAFENONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, NORFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, MEXILETINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CIPROFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, ARMODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, ESOMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, FELBAMATE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOSUQUIDAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALSPODAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALPROATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TROLEANDOMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIFLUOPERAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRANYLCYPROMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIZANIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIPRANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIABENDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TENIPOSIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAPHENAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHIZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAQUINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RESERPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINUPRISTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUININE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUERCETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROMETHAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PILOCARPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENCYCLIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXYCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICARDIPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MOLINDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIFEPRISTONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LITHIUM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDOMETHACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IBUPROFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOROURACIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLECAINIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FEXOFENADINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETHANOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ELACRIDAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DROPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DOXORUBICIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIGOXIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIETHYLDITHIOCARBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESLORATADINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DELAVIRDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DARUNAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DANAZOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COLCHICINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOTRIMAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOMIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPHENIRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORAMPHENICOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BASILIXIMAB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1382, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1336, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1343, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1305, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1334, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1320, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS AN IN VIVO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1466, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1316, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1404, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1354, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1333, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1403, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN IS AN IN VIVO SELECTIVE INHIBITOR OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1494, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1402, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1647, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1401, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1321, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1353, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1304, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1379, </TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1326, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1342, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1313, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1378, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1352, </TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1325, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1303, </TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1332, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1302, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1399, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1376, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1351, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1364, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1397, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1396, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1322, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1363, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1338, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1330, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_981, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1324, </TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1347, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1394, </TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1312, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1329, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1340, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN IN VIVO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1470, </TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG IS AN IN VIVO SELECTIVE INHIBITOR OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1492, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1385, </TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1311, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1393, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1391, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1373, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1360, </TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1328, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1319, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1389, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1359, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1384, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1388, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1327, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1309, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1383, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1349, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1370, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1369, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1344, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1358, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1357, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1366, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1308, </TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1307, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_598, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1490, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1489, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1221, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1441, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1488, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1448, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1411, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1487, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1502, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1485, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1501, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8</TD><TD>BC SATISFIED ASSERTION_1239, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RIFAMPIN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1506, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1484, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1410, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1447, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1437, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1504, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1483, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PITAVASTATIN IS OATP1B3</TD><TD>BC SATISFIED ASSERTION_1514, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1453, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1418, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1451, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_711, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8</TD><TD>BC SATISFIED ASSERTION_1416, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1482, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1450, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1409, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1435, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1434, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1480, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1509, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1432, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1479, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1499, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1433, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FEXOFENADINE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1478, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1498, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1477, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1414, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1408, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1427, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1443, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIGOXIN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1476, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_373, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1426, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1425, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1475, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1474, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1442, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1424, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF COLCHICINE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1473, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1417, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1413, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1495, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1421, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1472, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1407, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1471, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_309, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_536, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019, ATORVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021, BETA HYDROXY LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C9 IS 0.01, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2D6 IS 0.013, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP0.032A4 IS 0.032, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP2C9 IS 0.005568, FLUOXETINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP0.004A4 IS 0.004, FLUOXETINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP1A2 IS 0.018, FLUPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP1A2, MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP2D6 IS 0.004, FLUPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008, FLUVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003, LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C19 IS 0.287, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C19, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C9 IS 0.223, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP0.153A4 IS 0.153, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP1A2 IS 0.026, PERPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP1A2, MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP2D6 IS 3.2e 4, PERPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF RISPERIDONE FOR CYP2D6 IS 0.003, RISPERIDONE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF RISPERIDONE IS 7.9e 5 AT DOSE 0.001, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_248, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1136, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_832, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1080, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_687, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_44, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_351, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_727, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_1001, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1022, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_349, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_718, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1094, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_910, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_1125, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_887, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1172, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_341, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_163, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_899, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_537, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_500, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_715, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1090, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_183, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_1117, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_685, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_538, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_868, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_984, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A1</TD><TD>BC SATISFIED ASSERTION_930, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_340, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_67, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_877, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_672, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_75, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_839, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_745, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_88, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_227, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_37, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_213, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_108, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_933, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_501, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_507, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1024, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1226, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_488, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_582, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_334, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_192, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_473, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_964, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_803, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_199, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_261, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_668, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_120, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1218, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_119, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_690, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1068, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_834, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_180, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_130, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_751, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_124, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1181, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_435, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_789, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_203, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1018, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1245, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1184, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_321, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_459, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_115, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_207, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_897, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_758, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_673, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_52, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_51, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_173, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_231, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_995, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1207, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_702, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_940, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1118, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_946, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_610, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_16, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_662, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_870, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_861, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_172, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_71, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1165, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_855, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1086, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_820, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_182, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_208, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_274, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_734, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_757, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_398, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_55, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_896, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_612, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_484, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_755, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_31, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_523, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_527, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_198, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_576, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_226, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1251, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_444, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_347, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_841, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_814, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1010, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1253, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1050, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_121, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1170, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1092, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_872, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_697, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_784, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_387, </TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR INHIBITS CYP1A2</TD><TD>ACYCLOVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL INHIBITS CYP1A2</TD><TD>ALLOPURINOL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS CYP3A4</TD><TD>ALPRAZOLAM IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS CYP3A4</TD><TD>AMPRENAVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS CYP3A4</TD><TD>APREPITANT IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL INHIBITS CYP2C19</TD><TD>ARMODAFINIL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS CYP3A4</TD><TD>BICALUTAMIDE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS CYP3A4</TD><TD>BOCEPREVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE INHIBITS CYP1A2</TD><TD>CAFFEINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE INHIBITS CYP2C9</TD><TD>CAPECITABINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4</TD><TD>CIPROFLOXACIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS CYP2D6</TD><TD>CLOBAZAM IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL INHIBITS CYP2B6</TD><TD>CLOPIDOGREL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9</TD><TD>COTRIMOXAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS CYP3A4</TD><TD>CRIZOTINIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS CYP3A4</TD><TD>CYCLOSPORINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6</TD><TD>DESVENLAFAXINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6</TD><TD>DIPHENHYDRAMINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM INHIBITS CYP1A2</TD><TD>DISULFIRAM IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG INHIBITS OATP1B1</TD><TD>ELTROMBOPAG IS AN IN VIVO SELECTIVE INHIBITOR OF OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN IS AN IN VIVO SELECTIVE INHIBITOR OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19</TD><TD>ESOMEPRAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS CYP2C9</TD><TD>ETRAVIRINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE INHIBITS CYP1A2</TD><TD>FAMOTIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS CYP2D6</TD><TD>FEBUXOSTAT IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE INHIBITS CYP2C19</TD><TD>FELBAMATE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN INHIBITS CYP2C9</TD><TD>FLUVASTATIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4</TD><TD>FOSAMPRENAVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS CYP2D6</TD><TD>HYDRALAZINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6</TD><TD>HYDROXYCHLOROQUINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS CYP3A4</TD><TD>IMATINIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS CYP3A4</TD><TD>ISONIAZID IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS CYP2D6</TD><TD>METHADONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN INHIBITS CYP1A2</TD><TD>METHOXSALEN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE INHIBITS CYP2C9</TD><TD>METRONIDAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE INHIBITS CYP2C9</TD><TD>MICONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS CYP3A4</TD><TD>NELFINAVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS CYP3A4</TD><TD>NILOTINIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE INHIBITS CYP2C9</TD><TD>OXANDROLONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS CYP3A4</TD><TD>PAZOPANIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2</TD><TD>PHENYLPROPANOLAMINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS CYP3A4</TD><TD>POSACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL INHIBITS CYP2B6</TD><TD>PRASUGREL IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP2D6</TD><TD>PROPAFENONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP3A4</TD><TD>QUINIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS CYP2D6</TD><TD>RANITIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN INHIBITS OATP1B1</TD><TD>RIFAMPIN IS AN IN VIVO SELECTIVE INHIBITOR OF OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9</TD><TD>SULFINPYRAZONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS CYP3A4</TD><TD>TELAPREVIR IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP2D6</TD><TD>TELITHROMYCIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP1A2</TD><TD>TERBINAFINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN</TD><TD>TICAGRELOR IS AN IN VIVO SELECTIVE INHIBITOR OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS CYP2B6</TD><TD>TICLOPIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE INHIBITS CYP2C9</TD><TD>TIGECYCLINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS CYP1A2</TD><TD>VEMURAFENIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS CYP3A4</TD><TD>ZILEUTON IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A5</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A5 IS 1.966e 6, KETOCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A5, MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR P GLYCOPROTEIN IS 0.002817, KETOCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF P GLYCOPROTEIN, MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_63, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_211, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_251, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_881, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_511, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_595, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_454, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1141, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_92, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_90, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_680, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1093, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_521, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1028, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1205, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1149, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_430, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_64, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_65, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_320, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1151, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1152, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_369, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1032, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_318, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1223, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1193, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_519, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_961, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1195, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_688, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_287, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE INHIBITS CYP1A2</TD><TD>MEXILETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A4</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A4 IS 1.966e 6, KETOCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1158, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_485, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_486, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_876, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_221, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_177, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_638, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A4</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP3.89e 4A4 IS 3.89e 4, FLUCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP2C9</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP2C9 IS 0.002144, FLUCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS CYP2D6</TD><TD>DULOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_714, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4</TD><TD>INHIBITION CONSTANT OF CLARITHROMYCIN FOR CYP0.00168A4 IS 0.00168, CLARITHROMYCIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF CLARITHROMYCIN IS 0.00251 AT DOSE 0.5, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_313, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS CYP2D6</TD><TD>CINACALCET IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1102, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1103, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1071, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS CYP2D6</TD><TD>CELECOXIB IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_854, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS CYP3A4</TD><TD>ATORVASTATIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_241, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_242, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_695, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_404, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_403, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1250, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, RIFAMPIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>GEMFIBROZIL INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF PACLITAXEL</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>GEMFIBROZIL INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSIGLITAZONE</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF PACLITAXEL</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSIGLITAZONE</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOPIDOGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOPIDOGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF ATRASENTAN</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF EZETIMIBE</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF IRINOTECAN</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF PRAVASTATIN</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF RIFAMPIN</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF RIFAMPIN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSUVASTATIN</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ELTROMBOPAG INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN ACID</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF ALISKIREN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF AMBRISENTAN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF COLCHICINE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF COLCHICINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN ETEXILATE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DIGOXIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DIGOXIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF FEXOFENADINE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF FEXOFENADINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF IMATINIB</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF LAPATINIB</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF NILOTINIB</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF POSACONAZOLE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SAXAGLIPTIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SITAGLIPTIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TALINOLOL</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOPOTECAN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVASTATIN INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVASTATIN INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVASTATIN INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVASTATIN INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PRASUGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PRASUGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RIFAMPIN INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF ATRASENTAN</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RIFAMPIN INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF EZETIMIBE</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RIFAMPIN INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RIFAMPIN INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF IRINOTECAN</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RIFAMPIN INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF PRAVASTATIN</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RIFAMPIN INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSUVASTATIN</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RIFAMPIN INHIBITS OATP1B1 THE PRIMARY TOTAL CLEARANCE ENZ OF SIMVASTATIN ACID</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1, PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF ALISKIREN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF AMBRISENTAN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF COLCHICINE</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF COLCHICINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN ETEXILATE</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DIGOXIN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DIGOXIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF FEXOFENADINE</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF FEXOFENADINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF IMATINIB</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF LAPATINIB</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF NILOTINIB</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF POSACONAZOLE</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SAXAGLIPTIN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SITAGLIPTIN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TALINOLOL</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOPOTECAN</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TACROLIMUS</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF ALISKIREN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF AMBRISENTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF COLCHICINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF COLCHICINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN ETEXILATE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DIGOXIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DIGOXIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF FEXOFENADINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF FEXOFENADINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF IMATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF LAPATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF NILOTINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF POSACONAZOLE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SAXAGLIPTIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SITAGLIPTIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TALINOLOL</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOPOTECAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>FLUVASTATIN INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-2</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY METABOLIC ENZYME OF ROSUVASTATIN</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE, PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_1233, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.2</TD><TD>BC SATISFIED ASSERTION_482, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VALPROATE IS 0.5</TD><TD>BC SATISFIED ASSERTION_889, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_197, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.025</TD><TD>BC SATISFIED ASSERTION_477, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 0.25</TD><TD>BC SATISFIED ASSERTION_983, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 0.84</TD><TD>BC SATISFIED ASSERTION_794, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 1.0</TD><TD>BC SATISFIED ASSERTION_185, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.065</TD><TD>BC SATISFIED ASSERTION_1033, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.0125</TD><TD>BC SATISFIED ASSERTION_998, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.02</TD><TD>BC SATISFIED ASSERTION_622, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.06</TD><TD>BC SATISFIED ASSERTION_754, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.03</TD><TD>BC SATISFIED ASSERTION_23, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 0.75</TD><TD>BC SATISFIED ASSERTION_429, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.01</TD><TD>BC SATISFIED ASSERTION_1208, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.015</TD><TD>BC SATISFIED ASSERTION_1060, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.02</TD><TD>BC SATISFIED ASSERTION_935, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.2</TD><TD>BC SATISFIED ASSERTION_589, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.01</TD><TD>BC SATISFIED ASSERTION_368, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_512, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.6</TD><TD>BC SATISFIED ASSERTION_599, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VALPROATE IS 4.2</TD><TD>BC SATISFIED ASSERTION_317, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_214, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.4</TD><TD>BC SATISFIED ASSERTION_1131, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 3.0</TD><TD>BC SATISFIED ASSERTION_4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 1.05</TD><TD>BC SATISFIED ASSERTION_647, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 2.0</TD><TD>BC SATISFIED ASSERTION_505, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.6</TD><TD>BC SATISFIED ASSERTION_307, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.15</TD><TD>BC SATISFIED ASSERTION_1150, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.24</TD><TD>BC SATISFIED ASSERTION_738, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.12</TD><TD>BC SATISFIED ASSERTION_135, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.04</TD><TD>BC SATISFIED ASSERTION_186, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 4.0</TD><TD>BC SATISFIED ASSERTION_164, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.2</TD><TD>BC SATISFIED ASSERTION_924, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.18</TD><TD>BC SATISFIED ASSERTION_1008, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.8</TD><TD>BC SATISFIED ASSERTION_25, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.8</TD><TD>BC SATISFIED ASSERTION_967, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.08</TD><TD>BC SATISFIED ASSERTION_1089, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ZOSUQUIDAR FOR P GLYCOPROTEIN IS 1.529e 5</TD><TD>BC SATISFIED ASSERTION_1628, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ZIPRASIDONE FOR CYP2D6 IS 0.005</TD><TD>BC SATISFIED ASSERTION_154, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR P GLYCOPROTEIN IS 0.003637</TD><TD>BC SATISFIED ASSERTION_1633, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR CYP0.004546A5 IS 0.004546</TD><TD>BC SATISFIED ASSERTION_1574, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR CYP0.004546A4 IS 0.004546</TD><TD>BC SATISFIED ASSERTION_1570, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VALSPODAR FOR P GLYCOPROTEIN IS 1.336e 4</TD><TD>BC SATISFIED ASSERTION_1632, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRYPTAMINE FOR CYP2A6 IS 0.001643</TD><TD>BC SATISFIED ASSERTION_1527, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TROLEANDOMYCIN FOR CYP2.198e 4A5 IS 2.198e 4</TD><TD>BC SATISFIED ASSERTION_1573, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TROLEANDOMYCIN FOR CYP2.198e 4A4 IS 2.198e 4</TD><TD>BC SATISFIED ASSERTION_1569, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRIMETHOPRIM FOR CYP2C8 IS 0.00929</TD><TD>BC SATISFIED ASSERTION_1547, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRANYLCYPROMINE FOR CYP2A6 IS 2.664e 6</TD><TD>BC SATISFIED ASSERTION_1524, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2C19 IS 3.165e 4</TD><TD>BC SATISFIED ASSERTION_1020, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2B6 IS 5.276e 5</TD><TD>BC SATISFIED ASSERTION_352, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIOTHIXENE FOR CYP2D6 IS 0.029</TD><TD>BC SATISFIED ASSERTION_293, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIOTEPA FOR CYP2B6 IS 9.082e 4</TD><TD>BC SATISFIED ASSERTION_1539, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIORIDAZINE FOR CYP2D6 IS 5.699e 4</TD><TD>BC SATISFIED ASSERTION_1230, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TACROLIMUS FOR P GLYCOPROTEIN IS 5.95e 4</TD><TD>BC SATISFIED ASSERTION_1631, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SULFAPHENAZOLE FOR CYP2C9 IS 4.087e 4</TD><TD>BC SATISFIED ASSERTION_1553, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SIMVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_256, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SERTRALINE FOR CYP2B6 IS 9.799e 4</TD><TD>BC SATISFIED ASSERTION_1537, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ROSIGLITAZONE FOR CYP2C8 IS 0.002002</TD><TD>BC SATISFIED ASSERTION_767, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF RISPERIDONE FOR CYP2D6 IS 0.003</TD><TD>BC SATISFIED ASSERTION_625, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF RESERPINE FOR P GLYCOPROTEIN IS 8.522e 4</TD><TD>BC SATISFIED ASSERTION_1635, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUINIDINE FOR P GLYCOPROTEIN IS 7.137e 4</TD><TD>BC SATISFIED ASSERTION_1630, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUINIDINE FOR CYP2D6 IS 8.759e 5</TD><TD>BC SATISFIED ASSERTION_1560, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUERCETIN FOR CYP2C8 IS 0.001871</TD><TD>BC SATISFIED ASSERTION_1546, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PIOGLITAZONE FOR CYP2C8 IS 6.059e 4</TD><TD>BC SATISFIED ASSERTION_636, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PILOCARPINE FOR CYP2A6 IS 8.33e 4</TD><TD>BC SATISFIED ASSERTION_1526, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PHENCYCLIDINE FOR CYP2B6 IS 0.002434</TD><TD>BC SATISFIED ASSERTION_1538, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP2D6 IS 3.2e 4</TD><TD>BC SATISFIED ASSERTION_569, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP1A2 IS 0.026</TD><TD>BC SATISFIED ASSERTION_144, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PALIPERIDONE FOR CYP2D6 IS 0.007</TD><TD>BC SATISFIED ASSERTION_442, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP0.153A4 IS 0.153</TD><TD>BC SATISFIED ASSERTION_749, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C9 IS 0.223</TD><TD>BC SATISFIED ASSERTION_446, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C19 IS 0.287</TD><TD>BC SATISFIED ASSERTION_824, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NORFLUOXETINE FOR CYP4.252e 4A4 IS 4.252e 4</TD><TD>BC SATISFIED ASSERTION_613, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NOOTKATONE FOR CYP2C19 IS 1.092e 4</TD><TD>BC SATISFIED ASSERTION_1559, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NELFINAVIR FOR P GLYCOPROTEIN IS 7.949e 4</TD><TD>BC SATISFIED ASSERTION_1629, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF MONTELUKAST FOR CYP2C8 IS 6.448e 4</TD><TD>BC SATISFIED ASSERTION_542, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF METHOXSALEN FOR CYP2A6 IS 2.162e 6</TD><TD>BC SATISFIED ASSERTION_1525, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_118, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR P GLYCOPROTEIN IS 0.002817</TD><TD>BC SATISFIED ASSERTION_1627, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A5 IS 1.966e 6</TD><TD>BC SATISFIED ASSERTION_1571, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A4 IS 1.966e 6</TD><TD>BC SATISFIED ASSERTION_859, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ITRACONAZOLE FOR CYP1.905e 4A5 IS 1.905e 4</TD><TD>BC SATISFIED ASSERTION_1572, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ITRACONAZOLE FOR CYP1.905e 4A4 IS 1.905e 4</TD><TD>BC SATISFIED ASSERTION_943, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF HALOPERIDOL FOR CYP2D6 IS 0.003</TD><TD>BC SATISFIED ASSERTION_676, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF GEMFIBROZIL FOR CYP2C8 IS 0.01727</TD><TD>BC SATISFIED ASSERTION_1548, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FURAFYLLINE FOR CYP1A2 IS 1.562e 4</TD><TD>BC SATISFIED ASSERTION_1518, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVOXAMINE FOR CYP2C9 IS 0.002037</TD><TD>BC SATISFIED ASSERTION_1555, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVOXAMINE FOR CYP1A2 IS 2.072e 5</TD><TD>BC SATISFIED ASSERTION_316, THEOPHYLLINE IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008</TD><TD>BC SATISFIED ASSERTION_1105, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP2D6 IS 0.004</TD><TD>BC SATISFIED ASSERTION_421, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP1A2 IS 0.018</TD><TD>BC SATISFIED ASSERTION_322, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP0.004A4 IS 0.004</TD><TD>BC SATISFIED ASSERTION_725, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP2C9 IS 0.005568</TD><TD>BC SATISFIED ASSERTION_1556, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP3.89e 4A4 IS 3.89e 4</TD><TD>BC SATISFIED ASSERTION_560, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP2C9 IS 0.002144</TD><TD>BC SATISFIED ASSERTION_1554, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ERYTHROMYCIN FOR CYP0.006A4 IS 0.006</TD><TD>BC SATISFIED ASSERTION_643, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ELACRIDAR FOR P GLYCOPROTEIN IS 2.255e 4</TD><TD>BC SATISFIED ASSERTION_1634, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF DILTIAZEM FOR CYP2.2e 4A4 IS 2.2e 4</TD><TD>BC SATISFIED ASSERTION_416, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF DIETHYLDITHIOCARBAMATE FOR CYP2E1 IS 0.00214</TD><TD>BC SATISFIED ASSERTION_1562, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CYCLOSPORINE FOR P GLYCOPROTEIN IS 6.013e 4</TD><TD>BC SATISFIED ASSERTION_1626, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP0.032A4 IS 0.032</TD><TD>BC SATISFIED ASSERTION_781, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2D6 IS 0.013</TD><TD>BC SATISFIED ASSERTION_448, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C9 IS 0.01</TD><TD>BC SATISFIED ASSERTION_785, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C19 IS 0.023</TD><TD>BC SATISFIED ASSERTION_677, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOPIDOGREL FOR CYP2B6 IS 1.609e 4</TD><TD>BC SATISFIED ASSERTION_453, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLARITHROMYCIN FOR CYP0.00168A4 IS 0.00168</TD><TD>BC SATISFIED ASSERTION_41, TESTOSTERONE IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY SIMVASTATIN FOR CYP2C8 IS 0.018</TD><TD>BC SATISFIED ASSERTION_869, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021</TD><TD>BC SATISFIED ASSERTION_566, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019</TD><TD>BC SATISFIED ASSERTION_770, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ALPHA NAPHTHOFLAVONE FOR CYP1A2 IS 2.723e 5</TD><TD>BC SATISFIED ASSERTION_1519, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF 9 HYDROXYRISPERIDONE FOR CYP2D6 IS 0.007</TD><TD>BC SATISFIED ASSERTION_142, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CYP2B6 ISOPROPENYL CYP2B6 METHYL ADAMANTANE FOR CYP2B6 IS 0.001009</TD><TD>BC SATISFIED ASSERTION_1536, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS SUBSTRATE OF CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP2E1</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP2E1 DIMETHYLURIC ACID VIA CYP2E1, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF COLCHICINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIGOXIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FEXOFENADINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS SUBSTRATE OF CYP2C8</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PITAVASTATIN IS OATP1B3, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RIFAMPIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS SUBSTRATE OF CYP2C8</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_591, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_719, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_640, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_298, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_547, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_383, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_654, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_895, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_796, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_957, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_580, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1169, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_494, CYP2C19 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_480, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1129, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1228, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_577, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1002, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_533, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_254, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1044, FLUOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_152, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1030, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_890, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1206, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_838, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_532, FLUOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_780, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_712, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_59, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_58, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_802, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_181, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_700, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_9, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_966, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_856, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1019, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_194, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_239, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_632, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_98, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_89, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_611, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM PERMANENTLY DEACTIVATES CATALYTIC FUNCTION OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_259, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE METHYL HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THREOHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE 5 SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE 6B HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERFENADINE C HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAXOL 6 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE 1 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE PARA HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>REDUCED HALOPERIDOL IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOFOL HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN O DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL 3 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE 5 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORPROPOXYPHENE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLUOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NIFEDIPINE OXIDATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICOTINE C OXIDATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM 1 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAURIC ACID 11 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXY HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLURBIPROFEN 4’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE O DEALKYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ HYDROXYLASE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DICLOFENAC 4’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN O DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESMETHYLCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESGLYMIDODRINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN 7 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE 6 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE 3 N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUFURALOL 1’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ANILINE 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMODIAQUINE N DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA NAPHTHOFLAVONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S ZOPICLONE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN 7 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S METHYL DIHYDROZIPRASIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN 4’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S N DESMETHYLZOPICLONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>O DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLTAMOXIFEN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLSERTRALINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYL_ERYTHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>M CHLOROPHENYLPIPERAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>9 HYDROXYRISPERIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYPERPHENAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY N DESALKYL QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN O DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXYMETHYL SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6BETA HYDROXYTESTOSTERONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTRIAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTAMOXIFIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYDEBRISOQUINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3ALPHA HYDROXYPRAVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>2 ISOPROPENYL 2 METHYL ADAMANTANE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1PRIME HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>14 HYDROXYCLARITHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>10 N GLUCURONIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1,3 DIMETHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS ANCESTOR OF 3 METHYLXANTHINE</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS ANCESTOR OF HYDROXYBUPROPION</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS ANCESTOR OF N DESMETHYLATOMOXETINE</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS ANCESTOR OF N DESMETHYLSERTRALINE</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS ANCESTOR OF N DESMETHYLROSUVASTATIN</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS ANCESTOR OF 4 HYDROXYATOMOXETINE</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS ANCESTOR OF 9 HYDROXYRISPERIDONE</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS ANCESTOR OF 1,3 DIMETHYLURIC ACID</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, </TD></TR><BR>
<TR><TD>(BC-SATISFIED 'ASSERTION_950)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_934)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_928)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_914)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_91)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_909)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_893)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_822)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_821)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_800)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_769)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_752)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_740)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_736)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_728)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_720)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_708)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_703)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_70)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_689)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_686)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_615)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_579)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_568)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_559)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_557)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_543)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_503)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_493)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_472)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_45)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_440)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_425)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_354)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_344)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_33)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_314)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_30)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_240)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_138)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1297)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1294)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1292)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1288)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1286)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1284)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1281)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1279)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1278)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1277)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1273)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1267)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1266)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1243)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1217)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1215)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1212)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1171)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_116)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1157)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1106)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_110)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1087)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1078)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1067)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1053)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_103)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1007)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1003)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_250)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1074)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1034)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_438)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_134)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_614)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_900)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_982)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_69)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_853)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_106)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1069)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_539)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_681)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_760)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1128)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1064)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_990)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_645)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1061)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_141)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1261)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_891)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_462)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1059)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_642)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_140)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_10)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_279)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_450)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_269)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_634)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_32)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1039)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_515)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1041)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_729)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_15)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_972)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1037)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_644)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_158)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_238)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_919)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_556)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_962)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_598)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1490)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1489)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1221)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1441)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1488)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1448)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1411)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1487)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1502)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1485)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1501)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1239)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1506)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1484)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1410)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1447)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1437)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1504)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1483)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1453)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1418)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1451)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_711)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1482)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1450)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1435)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1480)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1509)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1432)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1479)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1499)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1433)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1478)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1498)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1477)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1414)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1408)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1427)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1476)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_373)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1426)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1425)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1475)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1474)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1442)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1424)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1473)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1417)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1413)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_77)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_228)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1146)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1421)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1472)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1407)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1471)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_309)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_536)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_816)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1013)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1122)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1047)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1233)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_482)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_889)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_477)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_983)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_794)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_185)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1033)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_998)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_754)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_23)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_429)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1060)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_935)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_368)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_512)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_599)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_317)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_4)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_647)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_505)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1150)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_738)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_135)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_924)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1008)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_25)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_967)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1089)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_813)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_698)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_275)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_867)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_884)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_267)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_464)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_605)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_541)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_466)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1232)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_655)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1017)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_104)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_594)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1179)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_806)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_844)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1023)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1085)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_518)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_455)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_921)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_788)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_423)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_629)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_224)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_865)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_312)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_942)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_101)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1148)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_741)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_49)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_880)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_154)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1633)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1574)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1570)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1632)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1527)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1573)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1569)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1547)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1524)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1020)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_352)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_293)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1539)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1230)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1553)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_256)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1537)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_767)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_625)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1630)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1560)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1546)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_636)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1526)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1538)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_569)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_144)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_442)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_749)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_446)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_824)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_613)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1559)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1629)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_542)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1525)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_118)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1627)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_859)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1572)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_943)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_676)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1548)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1518)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1555)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_316)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1105)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_421)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_322)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_725)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1556)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_560)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1554)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_643)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1634)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1562)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1626)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_781)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_448)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_785)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_677)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_453)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_41)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_869)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_566)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_770)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1519)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_142)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1536)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_694)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_912)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1025)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_666)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1091)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_66)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_846)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_348)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_762)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_678)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_581)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_674)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_894)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_467)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1220)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_664)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1162)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_402)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_8)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1063)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_637)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_259)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_591)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_592)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1040)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_719)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_640)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_547)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_383)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1225)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_546)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_654)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_895)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_796)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_957)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_580)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1169)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_36)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_494)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_670)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_480)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_721)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1188)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_469)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1228)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1112)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_577)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_297)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1002)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_533)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_254)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1044)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_139)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1030)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1029)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1143)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_302)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_890)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_838)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_753)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_532)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_691)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_780)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_712)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_59)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_58)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_802)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_181)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_187)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_407)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_465)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_127)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_700)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_9)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_265)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_367)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_262)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_922)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_573)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_966)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_856)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1019)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_194)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_239)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_422)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1227)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_47)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_48)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_552)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_632)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_98)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_97)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_376)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_483)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_864)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_148)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_89)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_611)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_931)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_411)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_724)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_268)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_809)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_810)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_40)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_650)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_786)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_879)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_882)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_669)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_128)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_684)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_679)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_829)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_528)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_907)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_358)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_944)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_878)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_14)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1076)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_958)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_665)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_137)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1623)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1523)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1542)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1520)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1534)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1532)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1621)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1190)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1549)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1530)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1544)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1625)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1541)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1545)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1522)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1531)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1558)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1540)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1521)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1543)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1552)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1550)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1561)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1533)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1564)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1529)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_905)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_815)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1577)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_311)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_437)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1609)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1586)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1615)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1579)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1613)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1584)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1593)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1575)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_278)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_692)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1601)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_948)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1595)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1134)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1610)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1581)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1604)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_565)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1592)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1606)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_346)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1582)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1611)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1598)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1607)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_61)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1599)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_842)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1580)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_561)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1600)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_426)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1578)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1583)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_744)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1603)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1587)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_234)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1585)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1594)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_607)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1576)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_399)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1382)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1336)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1343)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1305)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1334)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1320)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1466)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1316)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1404)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1354)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1333)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1403)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1494)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1402)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1647)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1401)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1321)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1353)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1304)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1379)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1326)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1342)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1378)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1352)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1325)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1303)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1332)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1302)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1399)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1376)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1351)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1364)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1397)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1322)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1363)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1338)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1330)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_981)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1324)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1347)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1394)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1312)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1329)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1340)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1470)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1492)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1385)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1311)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1393)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1391)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1373)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1360)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1328)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1319)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1389)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1359)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1384)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1327)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1309)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1383)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1349)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1370)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1369)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1344)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1358)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1357)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1366)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1308)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_468)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_294)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_658)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_102)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_433)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1211)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_424)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_63)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_211)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_881)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_511)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_595)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_454)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1141)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_92)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_90)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_680)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1093)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_521)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1028)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1149)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_989)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_430)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_64)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_65)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_320)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_369)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1032)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_318)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1223)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1193)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_519)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_961)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1195)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_688)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_630)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1158)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_485)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_486)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_876)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_929)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_221)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1055)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_177)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_638)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_29)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_111)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_764)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_371)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_714)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_713)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1057)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1102)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1103)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1071)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_854)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1015)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_241)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_242)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_695)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_404)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_403)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1250)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_947)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_617)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1116)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_731)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_191)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_735)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_492)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_797)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_305)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_395)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1203)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_722)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_220)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_308)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1140)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_414)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_18)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1210)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_652)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_766)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_850)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1095)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1006)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_427)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1204)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_705)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1042)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_497)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_12)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_992)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_263)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1100)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_38)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1000)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_196)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_871)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_85)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1259)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_848)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_978)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_971)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_901)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_417)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_544)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_570)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_826)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_179)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1109)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_585)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_3)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_706)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1110)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1234)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_46)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_535)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_260)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_833)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_746)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_113)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_945)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_476)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_540)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_801)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_496)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_847)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_122)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1099)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_653)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_248)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1136)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_832)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1080)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_687)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_44)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_351)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_727)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1001)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1022)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_349)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_718)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1094)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_910)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1125)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_887)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_341)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_163)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1222)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_899)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_537)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_500)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_715)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1090)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_183)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1117)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_685)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_538)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_868)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_984)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_930)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_340)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_67)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_877)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_672)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_75)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_839)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_745)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_88)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_227)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_37)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_213)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_108)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_933)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_501)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_507)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1024)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1226)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_488)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_582)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_334)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_192)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_473)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_964)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_803)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_199)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_261)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_668)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_120)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1218)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_119)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_690)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1068)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_834)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_180)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_130)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_751)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_124)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1181)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_435)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_789)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_203)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1018)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1245)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1184)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_321)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_459)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_115)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_207)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_897)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_758)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_673)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_52)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_51)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_173)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_231)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_995)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1207)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_702)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_940)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1118)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_946)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_610)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_16)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_662)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_870)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_861)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_71)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1165)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_855)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_133)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1086)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_820)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_182)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_274)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_734)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_757)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_398)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_55)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_896)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_612)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_484)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_755)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_31)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_523)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_527)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_198)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_576)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_226)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_444)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_347)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_841)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_814)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1010)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1253)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1050)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_121)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1170)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1092)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_872)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_697)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_784)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_387)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_26)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_508)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_562)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_776)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1077)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_364)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_979)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_28)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_175)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_739)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_898)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_996)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1066)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_304)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_244)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_960)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_487)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_941)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_264)</TD></TR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1623, </TD></TR><BR>
<TR><TD>Z</TD><TD>VALSPODAR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1622, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRYPTAMINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1523, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1542, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRANYLCYPROMINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1520, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1534, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1532, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1621, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1190, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1549, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1530, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1544, </TD></TR><BR>
<TR><TD>Z</TD><TD>RESERPINE IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1625, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUERCETIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1541, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1545, </TD></TR><BR>
<TR><TD>Z</TD><TD>PILOCARPINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1522, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENCYCLIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1531, </TD></TR><BR>
<TR><TD>Z</TD><TD>NOOTKATONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1558, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1619, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1540, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1521, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1543, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1552, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1550, </TD></TR><BR>
<TR><TD>Z</TD><TD>ELACRIDAR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1624, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIETHYLDITHIOCARBAMATE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1561, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1616, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1533, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZAMULIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1564, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2B6 ISOPROPENYL CYP2B6 METHYL ADAMANTANE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1529, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1608, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_905, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE METHYL HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1589, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_815, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1577, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_311, </TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_437, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERFENADINE C HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1609, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAXOL 6 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1586, </TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS AN IN VITRO PROBE SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1615, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE 1 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1579, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN IN VITRO PROBE SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1613, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOFOL HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1584, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1593, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN O DEETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1575, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_278, </TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL 3 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1601, </TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_948, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE 5 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1595, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1134, </TD></TR><BR>
<TR><TD>Z</TD><TD>NIFEDIPINE OXIDATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1610, </TD></TR><BR>
<TR><TD>Z</TD><TD>NICOTINE C OXIDATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1581, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM 1 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1604, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_565, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAURIC ACID 11 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1602, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLURBIPROFEN 4’ HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1592, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1606, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_346, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ HYDROXYLASE IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1582, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIGOXIN IS AN IN VITRO PROBE SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1611, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN O DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1598, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1607, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_61, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1599, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_842, </TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN 7 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1580, </TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_561, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE 6 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1600, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_426, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE 3 N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1578, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1583, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_744, </TD></TR><BR>
<TR><TD>Z</TD><TD>ANILINE 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1603, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMODIAQUINE N DEETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1587, </TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_234, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1585, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN 4’ HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1594, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_607, </TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN O DEETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1576, </TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_399, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_692, </TD></TR><BR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         '2-ISOPROPENYL-2-METHYL-ADAMANTANE 'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         '9-HYDROXYRISPERIDONE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ALPHA-NAPHTHOFLAVONE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOPIDOGREL
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'CYCLOSPORINE 'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'DIETHYLDITHIOCARBAMATE 'CYP2E1)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ELACRIDAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUCONAZOLE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUCONAZOLE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUOXETINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUOXETINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'FLUPHENAZINE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'FLUPHENAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVOXAMINE
         'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVOXAMINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FURAFYLLINE
         'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'GEMFIBROZIL
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'HALOPERIDOL
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ITRACONAZOLE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ITRACONAZOLE 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'METHOXSALEN
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'MONTELUKAST
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'NELFINAVIR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'NOOTKATONE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'NORFLUOXETINE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PALIPERIDONE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PERPHENAZINE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PERPHENAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PHENCYCLIDINE 'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'PILOCARPINE
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PIOGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUERCETIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUINIDINE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUINIDINE
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'RESERPINE
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'RISPERIDONE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ROSIGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'SERTRALINE
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'SULFAPHENAZOLE 'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TACROLIMUS
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'THIORIDAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'THIOTEPA
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'THIOTHIXENE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TRANYLCYPROMINE 'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TRIMETHOPRIM 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TROLEANDOMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TROLEANDOMYCIN 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TRYPTAMINE
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VALSPODAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ZIPRASIDONE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ZOSUQUIDAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'SIMVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'LOVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ERYTHROMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'CLARITHROMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-SIMVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-LOVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ATORVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE ZIPRASIDONE SULPHOXIDE</TD><TD>BC SATISFIED ASSERTION_947, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE BENZISOTHIAZOLE SULPHOXIDE</TD><TD>BC SATISFIED ASSERTION_617, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE BENZISOTHIAZOLE SULPHONE</TD><TD>BC SATISFIED ASSERTION_1116, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE S METHYL DIHYDROZIPRASIDONE</TD><TD>BC SATISFIED ASSERTION_731, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE HAS METABOLITE VORICONAZOLE N OXIDE</TD><TD>BC SATISFIED ASSERTION_191, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_735, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_492, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE HAS METABOLITE M CHLOROPHENYLPIPERAZINE</TD><TD>BC SATISFIED ASSERTION_797, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE THIORIDAZINE 5 SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_305, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE SULFORIDAZINE</TD><TD>BC SATISFIED ASSERTION_395, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE MESORIDAZINE</TD><TD>BC SATISFIED ASSERTION_635, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE CAFFEINE</TD><TD>BC SATISFIED ASSERTION_1203, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 3 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_722, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_220, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_308, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN HAS METABOLITE N DESMETHYLTAMOXIFEN</TD><TD>BC SATISFIED ASSERTION_1140, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN HAS METABOLITE 4 HYDROXYTAMOXIFIN</TD><TD>BC SATISFIED ASSERTION_414, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN HAS METABOLITE BETA HYDROXY SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_18, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE</TD><TD>BC SATISFIED ASSERTION_1210, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN</TD><TD>BC SATISFIED ASSERTION_652, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_766, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE QUETIAPINE SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_850, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE N DESALKYLQUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1095, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1252, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY N DESALKYL QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1006, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE HAS METABOLITE NORPROPOXYPHENE</TD><TD>BC SATISFIED ASSERTION_427, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN HAS METABOLITE 3ALPHA HYDROXYPRAVASTATIN</TD><TD>BC SATISFIED ASSERTION_1204, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE HAS METABOLITE 7 HYDROXYPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_705, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE HAS METABOLITE 10 N GLUCURONIDE</TD><TD>BC SATISFIED ASSERTION_1042, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL HAS METABOLITE MODAFINIL SULFONE</TD><TD>BC SATISFIED ASSERTION_497, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE HAS METABOLITE DESGLYMIDODRINE</TD><TD>BC SATISFIED ASSERTION_12, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN HAS METABOLITE BETA HYDROXY LOVASTATIN</TD><TD>BC SATISFIED ASSERTION_992, </TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE HAS METABOLITE TERIFLUNOMIDE</TD><TD>BC SATISFIED ASSERTION_263, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL HAS METABOLITE REDUCED HALOPERIDOL</TD><TD>BC SATISFIED ASSERTION_1100, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE HAS METABOLITE NORFLUOXETINE</TD><TD>BC SATISFIED ASSERTION_38, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE HAS METABOLITE S ZOPICLONE N OXIDE</TD><TD>BC SATISFIED ASSERTION_1000, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE HAS METABOLITE S N DESMETHYLZOPICLONE</TD><TD>BC SATISFIED ASSERTION_196, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM HAS METABOLITE S DIDEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_871, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM HAS METABOLITE S DEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_85, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE DESACETYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_1259, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_848, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDESACETYL DILTIAZEM</TD><TD>BC SATISFIED ASSERTION_978, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE DESMETHYLCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_971, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE CLOZAPINE N OXIDE</TD><TD>BC SATISFIED ASSERTION_289, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE 7 HYDROXYCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_901, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN</TD><TD>BC SATISFIED ASSERTION_417, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM HAS METABOLITE DIDEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_544, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM HAS METABOLITE DEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_570, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET HAS METABOLITE HYDROXY HYDROCINNAMIC ACID</TD><TD>BC SATISFIED ASSERTION_826, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET HAS METABOLITE HYDROCINNAMIC ACID</TD><TD>BC SATISFIED ASSERTION_179, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE THREOHYDROBUPROPION</TD><TD>BC SATISFIED ASSERTION_1109, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION</TD><TD>BC SATISFIED ASSERTION_585, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE ERYTHROHYDROBUPROPION</TD><TD>BC SATISFIED ASSERTION_3, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME HYDROXYMETHYL SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_706, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME HYDROXY SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_1110, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME EXOMETHYLENE SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_1234, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_46, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_535, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_260, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_833, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE HAS METABOLITE DEHYDRO ARIPIPRAZOLE</TD><TD>BC SATISFIED ASSERTION_746, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM HAS METABOLITE ALPHA HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_1176, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM HAS METABOLITE 4 HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_113, </TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE HAS METABOLITE 1 METHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_945, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN IN VIVO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_468, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_294, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_658, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_102, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2D6 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_433, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2C9 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_1211, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2C19 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_424, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_931, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_411, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_724, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_268, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_809, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_810, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_40, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_650, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_786, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_879, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A1</TD><TD>BC SATISFIED ASSERTION_882, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_669, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_128, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_679, SULPHAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_528, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_907, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_358, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_944, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_878, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_14, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1076, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_958, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A1</TD><TD>BC SATISFIED ASSERTION_665, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ZALEPLON IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_694, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF VORICONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_912, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF TRAZODONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1025, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_666, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RISPERIDONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_495, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RABEPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1091, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PANTOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_151, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PALIPERIDONE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_628, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF NICARDIPINE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_290, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIRTAZAPINE IS MEDIUM HIGH</TD><TD>BC SATISFIED ASSERTION_66, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIDODRINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_846, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LOVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_348, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LANSOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_762, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF INDOMETHACIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_678, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVOXAMINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_581, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVASTATIN IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_674, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUPHENAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_894, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUCONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_420, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ESCITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_467, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF DILTIAZEM IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_1220, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_664, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_1162, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CHLORPROMAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_402, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATORVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_8, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATOMOXETINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1063, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ARIPIPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_637, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ALPRAZOLAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_631, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZOLPIDEM IS 1.06e 4 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_813, ASSUMED EFFECTIVE DOSE OF ZOLPIDEM IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZIPRASIDONE IS 1.0.1294e 4 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_698, ASSUMED EFFECTIVE DOSE OF ZIPRASIDONE IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VORICONAZOLE IS 4.66e 4 AT DOSE 0.6</TD><TD>BC SATISFIED ASSERTION_275, ASSUMED EFFECTIVE DOSE OF VORICONAZOLE IS 0.6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VENLAFAXINE IS 0.45.90.45e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_867, ASSUMED EFFECTIVE DOSE OF VENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF TRAZODONE IS 0.002 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_884, ASSUMED EFFECTIVE DOSE OF TRAZODONE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF THREOHYDROBUPROPION IS 5.098e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_267, ASSUMED EFFECTIVE DOSE OF THREOHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ROSUVASTATIN IS 1.88e 5 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_464, ASSUMED EFFECTIVE DOSE OF ROSUVASTATIN IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RISPERIDONE IS 7.9e 5 AT DOSE 0.001</TD><TD>BC SATISFIED ASSERTION_605, ASSUMED EFFECTIVE DOSE OF RISPERIDONE IS 0.001, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RANOLAZINE IS 2.6e 4 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_541, ASSUMED EFFECTIVE DOSE OF RANOLAZINE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_466, ASSUMED EFFECTIVE DOSE OF PERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PANTOPRAZOLE IS 2.5e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1219, ASSUMED EFFECTIVE DOSE OF PANTOPRAZOLE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125</TD><TD>BC SATISFIED ASSERTION_1232, ASSUMED EFFECTIVE DOSE OF OLANZAPINE IS 0.0125, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF METRONIDAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_655, ASSUMED EFFECTIVE DOSE OF METRONIDAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1017, ASSUMED EFFECTIVE DOSE OF LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LANSOPRAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_104, ASSUMED EFFECTIVE DOSE OF LANSOPRAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_594, ASSUMED EFFECTIVE DOSE OF KETOCONAZOLE IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF HYDROXYBUPROPION IS 0.001 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_1179, ASSUMED EFFECTIVE DOSE OF HYDROXYBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_806, ASSUMED EFFECTIVE DOSE OF FLUVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012</TD><TD>BC SATISFIED ASSERTION_844, ASSUMED EFFECTIVE DOSE OF FLUPHENAZINE IS 0.012, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1023, ASSUMED EFFECTIVE DOSE OF FLUOXETINE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4</TD><TD>BC SATISFIED ASSERTION_514, ASSUMED EFFECTIVE DOSE OF FLUCONAZOLE IS 0.4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ESCITALOPRAM IS 5.002e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1085, ASSUMED EFFECTIVE DOSE OF ESCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ERYTHROHYDROBUPROPION IS 1.457e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_518, ASSUMED EFFECTIVE DOSE OF ERYTHROHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF DILTIAZEM IS 6.067e 5 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_455, ASSUMED EFFECTIVE DOSE OF DILTIAZEM IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_921, ASSUMED EFFECTIVE DOSE OF CLOZAPINE IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLARITHROMYCIN IS 0.00251 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_131, ASSUMED EFFECTIVE DOSE OF CLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CHLORPROMAZINE IS 0.1.79e 5 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_153, ASSUMED EFFECTIVE DOSE OF CHLORPROMAZINE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CELECOXIB IS 7.05e 5 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_788, ASSUMED EFFECTIVE DOSE OF CELECOXIB IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BUPROPION IS 1.44e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_624, ASSUMED EFFECTIVE DOSE OF BUPROPION IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_423, ASSUMED EFFECTIVE DOSE OF BETA HYDROXY LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08</TD><TD>BC SATISFIED ASSERTION_629, ASSUMED EFFECTIVE DOSE OF ATORVASTATIN IS 0.08, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ASENAPINE IS 4.e 6 AT DOSE 0.005</TD><TD>BC SATISFIED ASSERTION_224, ASSUMED EFFECTIVE DOSE OF ASENAPINE IS 0.005, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ARIPIPRAZOLE IS 4.52e 4 AT DOSE 0.03</TD><TD>BC SATISFIED ASSERTION_865, ASSUMED EFFECTIVE DOSE OF ARIPIPRAZOLE IS 0.03, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ALPRAZOLAM IS 0.003.7e 5 AT DOSE 0.003</TD><TD>BC SATISFIED ASSERTION_312, ASSUMED EFFECTIVE DOSE OF ALPRAZOLAM IS 0.003, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DIDEMETHYLCITALOPRAM IS 1.897e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_942, ASSUMED EFFECTIVE DOSE OF S DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DEMETHYLCITALOPRAM IS 1.40.047e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_101, ASSUMED EFFECTIVE DOSE OF S DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DIDEMETHYLCITALOPRAM IS 0.04.971e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1148, ASSUMED EFFECTIVE DOSE OF R DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DEMETHYLCITALOPRAM IS 1.946e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_741, ASSUMED EFFECTIVE DOSE OF R DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF O DESMETHYLVENLAFAXINE IS 6.86e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_49, ASSUMED EFFECTIVE DOSE OF O DESMETHYLVENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 7 HYDROXYPERPHENAZINE IS 5.09e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_880, ASSUMED EFFECTIVE DOSE OF 7 HYDROXYPERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 14 HYDROXYCLARITHROMYCIN IS 8.8e 4 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_1126, ASSUMED EFFECTIVE DOSE OF 14 HYDROXYCLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZOLPIDEM '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZIPRASIDONE '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VORICONAZOLE '0.6)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'TRAZODONE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'THREOHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ROSUVASTATIN '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RISPERIDONE '0.001)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RANOLAZINE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PANTOPRAZOLE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'OLANZAPINE '0.0125)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'METRONIDAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LANSOPRAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'KETOCONAZOLE '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'HYDROXYBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUPHENAZINE '0.012)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUOXETINE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUCONAZOLE '0.4)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ESCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ERYTHROHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'DILTIAZEM '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLOZAPINE '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CHLORPROMAZINE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CELECOXIB '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BUPROPION '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BETA-HYDROXY-LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ATORVASTATIN '0.08)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ASENAPINE '0.005)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ARIPIPRAZOLE '0.03)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ALPRAZOLAM '0.003)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'O-DESMETHYLVENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '7-HYDROXYPERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '14-HYDROXYCLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_1047, </TD></TR><BR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_219, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_816, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF RISPERIDONE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1013, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ALPRAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1122, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON SIMVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_250, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON LOVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1074, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY SIMVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1034, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY LOVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_438, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON ATORVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_134, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF N DEMETHYLDESACETYL DILTIAZEM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF S WARFARIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALISKIREN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALOSETRON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF AMBRISENTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF APREPITANT IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATRASENTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF BUPROPION IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CELECOXIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF COLCHICINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF COLCHICINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CONIVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CYCLOSPORINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DABIGATRAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DABIGATRAN ETEXILATE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DARIFENACIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DASATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESACETYLDILTIAZEM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DIGOXIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIGOXIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DIHYDROERGOTAMINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DRONEDARONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DULOXETINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EFAVIRENZ IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EVEROLIMUS IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EZETIMIBE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FEXOFENADINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FEXOFENADINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUTICASONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF IMATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF INDINAVIR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF IRINOTECAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LAPATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LURASIDONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MARAVIROC IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MELATONIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF NEBIVOLOL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF NILOTINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PACLITAXEL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PANTOPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PERPHENAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PHENYTOIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PIMOZIDE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PITAVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PITAVASTATIN IS OATP1B3, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF POSACONAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PRAVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUETIAPINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUINIDINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RAMELTEON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RANOLAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RIFAMPIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RIFAMPIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSIGLITAZONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SAXAGLIPTIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIMVASTATIN ACID IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SITAGLIPTIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TACRINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TACROLIMUS IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TALINOLOL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TICAGRELOR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOLBUTAMIDE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOLVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOPOTECAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VORICONAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ZIPRASIDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_614, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ZALEPLON IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_900, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VORICONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_982, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VENLAFAXINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_205, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VALPROATE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_69, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOPIRAMATE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_853, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THREOHYDROBUPROPION IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_106, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THEOPHYLLINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1069, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TAMOXIFEN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_539, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIMVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_681, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS BILIARY_EXCRETION</TD><TD>BC SATISFIED ASSERTION_760, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RISPERIDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1128, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RANOLAZINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1064, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RABEPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_990, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUETIAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_285, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PRAVASTATIN IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_645, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PERPHENAZINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1061, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PAROXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_141, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PANTOPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1261, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PALIPERIDONE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_891, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MOLINDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_462, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MODAFINIL IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1059, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LOVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_642, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LANSOPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_140, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF KETOCONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_10, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF INDOMETHACIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_279, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF HYDROXYBUPROPION IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_450, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVOXAMINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_269, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_634, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_32, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUCONAZOLE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_1039, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DULOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_515, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DILTIAZEM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1041, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESGLYMIDODRINE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_1214, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CLOZAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_729, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CITALOPRAM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_15, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CINACALCET IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_972, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CELECOXIB IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1037, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATORVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_644, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATOMOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_158, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ASENAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_238, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ARIPIPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_919, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALPRAZOLAM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_556, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF 9 HYDROXYRISPERIDONE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_962, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLARITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>GEMFIBROZIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>GEMFIBROZIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ITRACONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>KETOCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MEXILETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MEXILETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL SULFONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL SULFONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TRIMETHOPRIM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TRIMETHOPRIM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ACYCLOVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ACYCLOVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALLOPURINOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALLOPURINOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALPRAZOLAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMPRENAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>APREPITANT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARMODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARMODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BICALUTAMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BOCEPREVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAFFEINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAFFEINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAPECITABINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAPECITABINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAPECITABINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOPIDOGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOPIDOGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>COTRIMOXAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>COTRIMOXAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>COTRIMOXAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CRIZOTINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CYCLOSPORINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DISULFIRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DISULFIRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESOMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESOMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ETRAVIRINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ETRAVIRINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ETRAVIRINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FAMOTIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FAMOTIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FELBAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FELBAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FOSAMPRENAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>IMATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ISONIAZID DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHOXSALEN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHOXSALEN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METRONIDAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METRONIDAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METRONIDAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NELFINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NILOTINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OXANDROLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OXANDROLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OXANDROLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAZOPANIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PHENYLPROPANOLAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PHENYLPROPANOLAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>POSACONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRASUGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRASUGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SULFINPYRAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SULFINPYRAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SULFINPYRAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELAPREVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEFAZODONE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, NEFAZODONE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TIGECYCLINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TIGECYCLINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLARITHROMYCIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, CLARITHROMYCIN IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TIGECYCLINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZILEUTON DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OLANZAPINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, OLANZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, ILOPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>